Protein Engineering
Dual-action protein developed at Stanford better restricts blood vessel formation
Published in Clinical Trials Week, August 29th, 2011
In a paper published online Aug. 8 in the Proceedings of the National Academy of Sciences, researchers at Stanford University describe the creation of a new type of engineered protein that is significantly more effective at preventing the formation of blood vessels by targeting not one, but two of the chemical receptors that control the creation of new capillaries - a process known as angiogenesis. The study shows that the new...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2011-08-29)
More Articles from Clinical Trials Week
- Drug Development
AMRI Receives NIH Contract Award for the Development of Pre-Clinical Drug Candidates to Treat Diseases of the Nervous System - U.S. Food and Drug Administration
CEL-SCI Addresses Warning Letter in Regard to Statements on Its Corporate Website - Clinical Trial Research
CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine Leukocyte Interleukin, Injection - Hepatitis C Virus
Data on Hepatitis C Virus Discussed by L. Castells and Colleagues - Thalidomide Therapy
Data on Thalidomide Therapy Reported by E.A. Wilkes and Co-Researchers - Clinical Trial Research
Findings from Rush University Advance Knowledge in Clinical Trial Research - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
